Antibody Information
General Information of This Antibody
| Antibody ID | ANI0VYDTW |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-MSLN scFv |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG scFv |
|||||
| Antigen Name | Mesothelin (MSLN) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
LMB-100 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 71.43% (Day 6) | Positive MSLN expression (MSLN +++/++) | ||
| Method Description |
In vivo efficacy of LMB-100 and LMB-164 in an SW48 mouse xenograft model was evaluated. LMB-100 was administered i.v. at 2.5 mg/kg dose every other day for 6 days for two cycles with three days in between cycles.
|
||||
| In Vivo Model | SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 81.60% (Day 15) | Positive MSLN expression (MSLN +++/++) | ||
| Method Description |
Female nude mice were inoculated subcutaneously with SW48 cells in the right flank and underwent treatment beginning 10 days post inoculation. The model was treated with LMB-100 (2.5 mg/kg).
|
||||
| In Vivo Model | SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 86.30% (Day 9) | Positive MSLN expression (MSLN +++/++) | ||
| Method Description |
Female nude mice were inoculated subcutaneously with SW48 cells in the right flank and underwent treatment beginning 10 days post inoculation. The model was treated with LMB-100 (2.5 mg/kg).
|
||||
| In Vivo Model | SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 88.70% (Day 9) | Positive MSLN expression (MSLN +++/++) | ||
| Method Description |
Female nude mice were inoculated subcutaneously with SW48 cells in the right flank and underwent treatment beginning 10 days post inoculation. The model was treated with LMB-100 (2.5 mg/kg) in combination with Oxaliplatin.
|
||||
| In Vivo Model | SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 92.28% (Day 15) | Positive MSLN expression (MSLN +++/++) | ||
| Method Description |
Female nude mice were inoculated subcutaneously with SW48 cells in the right flank and underwent treatment beginning 10 days post inoculation. The model was treated with LMB-100 (2.5 mg/kg) in combination with Actinomycin D (0.3 mg/kg).
|
||||
| In Vivo Model | SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.55 ng/mL±0.06 ng/mL
|
Positive MSLN expression (MSLN +++/++) | ||
| Method Description |
KLM-1 pancreatic adenocarcinoma cells were treated with indicated concentrations of LMB-12, LMB-100, or LMB-164 anti-MSLN targeted RITs for 72 hours before WST-8 assay of cell viability.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | KLM-1 cells | CVCL_5146 | ||
LMB-164 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 78.15% (Day 6) | Positive MSLN expression (MSLN +++/++) | ||
| Method Description |
In vivo efficacy of LMB-100 and LMB-164 in an SW48 mouse xenograft model was evaluated. LMB-100 was administered i.v. at 2.5 mg/kg dose every other day for 6 days for two cycles with three days in between cycles.
|
||||
| In Vivo Model | SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.38 ng/mL±0.08 ng/mL
|
Positive MSLN expression (MSLN +++/++) | ||
| Method Description |
KLM-1 pancreatic adenocarcinoma cells were treated with indicated concentrations of LMB-12, LMB-100, or LMB-164 anti-MSLN targeted RITs for 72 hours before WST-8 assay of cell viability.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | KLM-1 cells | CVCL_5146 | ||
LMB-12 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.17 ng/mL±0.08 ng/mL
|
Positive MSLN expression (MSLN +++/++) | ||
| Method Description |
KLM-1 pancreatic adenocarcinoma cells were treated with indicated concentrations of LMB-12, LMB-100, or LMB-164 anti-MSLN targeted RITs for 72 hours before WST-8 assay of cell viability.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | KLM-1 cells | CVCL_5146 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.